[Use of levamisole in the combined therapy of patients with slowly progressing juvenile schizophrenia].
Immunomodulating drug Levamisole was studied as a component in the combined treatment of juvenile slow progredient schizophrenia. Apart from normalizing the immune parameters, the drug improved the patients' clinical conditions. Most prominent was its clinical effect in patients with immune system sensitive to the drug. The patient's condition ameliorated in relation with the features of his initial state. Treating the patients with depressive-asthenic states has yielded the best results. Weaker was the effect on patients with obsessive-phobic disorders. The least curable were senesto-hypochondriac and dysmorphophobic disorders with sensitive delusions of relation.
Sekirina
T P
TP
Mikheeva
T V
TV
Koliaskina
G I
GI
Tsutsul'kovskaia
M Ia
MIa
Orlova
V A
VA
D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D007978:Levamisole / Q000627:therapeutic use*; D008297:Male; D011619:Psychotropic Drugs / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology
D011619:Psychotropic Drugs; D007978:Levamisole
Ispol'zovanie levamizola v kompleksnoĭ terapii bol'nykh iunosheskoĭ maloprogredientnoĭ shizofrenieĭ.